AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

VENLAFAXINE 75.000 Mg ;

12 registrations across 1 African market— 12 active

Markets with VENLAFAXINE 75.000 Mg ;

Recent registrations

Brand / ProductMarketHolderStatusExpires
Venllamash 75 mg
Extended release capsules containing pellets
🇪🇬EgyptMash for pharmaceutical Industries and cosmetic - mash premiereactive
Idixor 75 mg
Tablets
🇪🇬EgyptInternational drug agency for pharmaceutical industry (IDI)active
EFFEGAD 75 mg
Extended release hard gelatin capsule
🇪🇬EgyptHikma Pharmaceuticals industriesactive
Venoxor 75mg
Tablets
🇪🇬Egyptuniversal pharmaceutical industries (unipharma)active
Venllamash 75 mg
Extended release capsules containing pellets
🇪🇬EgyptMash for pharmaceutical Industries and cosmetic - mash premiereactive
Venoxor 75mg
Tablets
🇪🇬Egyptuniversal pharmaceutical industries (unipharma)active
IDIXOR 75mg
Extended release hard gelatin capsule
🇪🇬EgyptInternational drug agency for pharmaceutical industry (IDI)active
Idixor 75 mg
Tablets
🇪🇬EgyptInternational drug agency for pharmaceutical industry (IDI)active
EFEXOR XR
Sustained Release Capsule
🇪🇬EgyptViatris Egyptactive
EFFEGAD 75 mg
Extended release hard gelatin capsule
🇪🇬EgyptHikma Pharmaceuticals industriesactive
IDIXOR 75mg
Extended release hard gelatin capsule
🇪🇬EgyptInternational drug agency for pharmaceutical industry (IDI)active
EFEXOR XR
Sustained Release Capsule
🇪🇬EgyptViatris Egyptactive

VENLAFAXINE 75.000 Mg ; in Africa — Regulatory Overview

VENLAFAXINE 75.000 Mg ; is registered across 1 African markets with 12 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Egypt. AfricaRegulatory refreshes this data daily from official government sources.

Of the 12 registrations, 12 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.